CD19 and congenital rubella syndrome: One study found that the prophylactic use of tocilizumab reduced the incidence of severe CRS and did not increase the risk of ICANS when infused with anti-CD19 CAR-T cells containing CD3ζ/4-1BB costimulatory signaling to treat NHL patients (Caimi et al., 2021).